Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antithymidylate resistance enables transgene selection and cell survival for T cells in the presence of 5-fluorouracil and antifolates.

Gene therapy·2015
Same author

Moving from tinkering in the garage to assembly line production: the manufacture of genetically modified T cells expressing chimeric antigen receptors (CARs) comes on line.

Cancer gene therapy·2015
Same author

Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor.

Cancer gene therapy·2015
Same author

Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.

Leukemia·2013
Same author

The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor.

Gene therapy·2011
Same author

Identifying candidate allogeneic NK-cell donors for hematopoietic stem-cell transplantation based on functional phenotype.

Leukemia·2010

Related Experiment Video

Updated: Jul 10, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Adoptive cellular immunotherapy for childhood malignancies.

L J N Cooper1

  • 1Department of Pediatrics, MD Anderson Cancer Center, Houston, TX 77030, USA. ljncooper@mdanderson.org

Bone Marrow Transplantation
|November 21, 2007
PubMed
Summary

T cells show promise in treating cancers, including rare pediatric tumors, through adoptive immunotherapy. This review highlights their potential and rationale for clinical trials in childhood malignancies.

Area of Science:

  • Immunology
  • Oncology
  • Cell Therapy

Background:

  • T cells are crucial for immune defense against pathogens and tumors.
  • Allogeneic T-cell infusion in hematopoietic stem-cell transplantation (HSCT) is a proven cell-based therapy for hematologic cancers.
  • Adoptive T-cell therapy for general cancer treatment, especially pediatric tumors, is underutilized.

Purpose of the Study:

  • To review the current status of T-cell-based adoptive immunotherapy.
  • To provide a rationale for conducting T-cell immunotherapy trials.
  • To emphasize the application of T-cell therapy in pediatric malignancies.

Main Methods:

  • Literature review of clinical trials and existing research on T-cell therapies.
  • Analysis of the efficacy and limitations of current T-cell-based treatments.

More Related Videos

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

Related Experiment Videos

Last Updated: Jul 10, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

  • Synthesis of evidence supporting adoptive T-cell therapy for cancer.

    • Main Results:

    • T cells demonstrate significant potential in preventing and treating various cancers.
    • Hematopoietic stem-cell transplantation (HSCT) serves as a successful model for T-cell-based therapy.
    • Pediatric tumors remain a largely unexplored area for T-cell immunotherapy.

    Conclusions:

    • Adoptive T-cell immunotherapy holds considerable promise for cancer treatment.
    • Further clinical trials are warranted to explore T-cell therapy's efficacy in pediatric malignancies.
    • Integrating T-cell therapies could expand treatment options for childhood cancers.